Rituximab, lenalidomide
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary CNS Lymphoma
Conditions
Primary CNS Lymphoma
Trial Timeline
Nov 2, 2020 → Nov 2, 2026
NCT ID
NCT04627753About Rituximab, lenalidomide
Rituximab, lenalidomide is a phase 2 stage product being developed by Celltrion for Primary CNS Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04627753. Target conditions include Primary CNS Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04627753 | Phase 2 | Recruiting |
Competing Products
20 competing products in Primary CNS Lymphoma
Other Products from Celltrion
Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85